Product news from the 04/17/07 news brief

Share this article:
Eli Lilly has launched its first prescription drug for pets in the US, a beef-flavored chewable tablet that helps treat dogs for separation anxiety. The drug, marketed under the name Reconcile, uses the same compound as Lilly’s blockbuster antidepressant Prozac. Reconcile is designed to be used in combination with behavior management training to help dogs that have difficulty being separated from their owner or family members. Revenue projections and pricing for Reconcile were not made available. Reconcile has one competitor on the market Clomicalm, which is made my Novartis. GlaxoSmithKline received approval from the FDA to market Altabax, a new treatment for impetigo caused by strains of staphylococcus aureus or streptococcus pyogenes, the two most common types of bacteria in this skin infection that commonly affects children. Widespread use of antibiotics has led to bacteria becoming resistant to some drugs, creating a need for new treatments. Sepracor announced that Brovana brand (arformoterol tartrate) inhalation solution is now available by prescription in pharmacies nationwide. Brovana is a long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. The FDA approved Novartis’ Reclast (zoledronic acid), a treatment for patients with the bone condition Paget's disease. Paget's disease is estimated to affect about one million people in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.